The COVID-19 Vaccine AstraZeneca was evaluated in clinical trials involving more than 23,000 participants. Adverse reactions were reported less frequently in older adults (over 55 years) than in younger people.

These reactions were usually mild or moderate in intensity and resolved within a few days after vaccination. The most frequent adverse reactions in these trials were pain at the injection site, fatigue, headache, myalgia (muscle pains), chills, arthralgia (joint pains), and fever these were each reported in more than 1 in 10 people. The COVID-19 Pfizer/BioNTech Vaccine was evaluated in clinical trials involving more than 44,000 participants. These side effects need to be continuously balanced against the expected benefits in preventing illness. Following review of data for the COVID-19 Vaccine Moderna vaccine, the MHRA and CHM experts also concluded that this vaccine can be used as a safe and effective booster dose.Īll vaccines and medicines have some side effects. The MHRA confirmed on 9 September 2021 that the COVID-19 vaccines made by Pfizer and AstraZeneca can be used as safe and effective booster doses. Data are available on the impact of the vaccination campaign in reducing infections and illness in the UK.

In clinical trials, the vaccines showed very high levels of protection against symptomatic infections with COVID-19. All have been authorised for supply by the Medicines and Healthcare products Regulatory Agency (MHRA) following a thorough review of safety, quality and efficacy information from clinical trials. Three COVID-19 vaccines - the COVID-19 Pfizer/BioNTech Vaccine, COVID-19 Vaccine AstraZeneca and COVID-19 Vaccine Moderna – are currently being used in the UK. A national immunisation campaign has been underway since early December 2020. Vaccination is the single most effective way to reduce deaths and severe illness from COVID-19. SummaryĪt the time of this report, over 146,936 people across the UK have died within 28 days of a positive test for coronavirus (COVID-19). We would ask anyone who suspects they have experienced a side effect linked with their COVID-19 vaccine to report via the Coronavirus Yellow Card website.

Robust safety monitoring and surveillance will continue to be carried out during this period. The publication on 13 January 2022 will contain data up to 5 January. The next publication will be on 6 January 2022 containing data up to 22 December 2021. Please note that over the holiday period the publication date of the Coronavirus vaccine - weekly summary of Yellow Card reporting will differ from usual. Note on publication during the holiday period

Stata 14 trial